CD8+T : Virus fighting white blood cells

[Guest Wiki]

Research has shown that HIV-fighting white blood cells called CD8+T cells are critical to the disease-fighting process. Previously, scientists had thought that a high number of these cells worked to control the progression of disease. This latest work, however, indicates it is the performance of the cells that provides the protective factor, and the cells’ production of a molecule called perforin that helps to kill off HIV-infected cells.

 

A new study suggests the difference is not the number but the quality of these cells: both nonprogressors and others have about the same number of HIV-fighting CD8+ T cells, but the cells of nonprogressors function better.

 

Long-term nonprogressors (LTNPs) are a group of individuals who are infected with HIV, but whose infection does not progress to AIDS. The elite controllers are a subset of this group who show an ability to suppress the HIV viral load to extremely low, often undetectable levels for an indefinite length of time. Some have been HIV positive for 30 years without developing the clinical symptoms of AIDS, in spite of never having been treated with highly active antiretroviral therapy. They have been the subject of a great deal of research, since an understanding of their ability to control HIV infection may lead to better anti-HIV drugs or a vaccine against HIV.

See also: HIV disease progression rates

 

It is estimated that as many as 1 in 100 people with HIV/AIDS are long-term nonprogessors, and as many as 1 in 300 are elite controllers. Since many LTNPs never develop the symptoms of AIDS, it is believed many of them do not know they are infected.

 

It is currently not known why long-term nonprogressors and elite controllers do not progress to AIDS. However, it has been shown that they are not simply infected with a weakened or inactive form of HIV. Many theories have been put forth suggesting the underlying mechanism of their resistance to infection. Most point to an inherited genetic trait that confers greater resistance or more robust immune response to HIV infection.

 

* Receptor mutations. A high percentage of long-term nonprogressors have been shown to have inherited mutations of the CCR5 receptor of T cell lymphocytes. HIV uses CCR5 to enter these cells. It is believed that the Δ32 (delta 32) variant of CCR5 impairs HIV ability to infect cells and cause disease. An understanding of this mechanism led to the development of a class of HIV medicines, the entry inhibitors.

 

* Antibody production. All individuals with HIV make antibodies against HIV. For reasons not completely understood, for most infected persons these antibodies do not prevent disease progression. The antibodies made against HIV by long-term nonprogressors, however, do seem to keep the virus in check. These antibodies seem to be targeted against highly conserved regions of HIV surface proteins, especially gp120 and gp41. Induction of similar antibodies in healthy individuals is a potential strategy for a HIV vaccine.

[Guest Wiki]

Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are identical because they are produced by one type of immune cell that are all clones of a single parent cell. Given almost any substance, it is possible to create monoclonal antibodies that specifically bind to that substance; they can then serve to detect or purify that substance. This has become an important tool in biochemistry, molecular biology and medicine. When used as medications, the generic drug name ends in -mab.